Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00397982
Other study ID # NCI-2009-00133
Secondary ID NCI-2009-00133NC
Status Completed
Phase Phase 2
First received November 9, 2006
Last updated July 28, 2016
Start date May 2007

Study information

Verified date December 2015
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase II trial is studying how well giving temsirolimus together with bevacizumab works in treating patients with stage III or stage IV malignant melanoma. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of malignant melanoma by blocking blood flow to the tumor. Giving temsirolimus together with bevacizumab may kill more tumor cells.


Description:

PRIMARY OBJECTIVES:

I. Determine the objective tumor response rate (complete response and partial response) in patients with stage III or IV melanoma treated with temsirolimus and bevacizumab.

SECONDARY OBJECTIVES:

I. Describe the adverse event profile of this regimen in these patients. II. Determine the efficacy of this regimen, in terms of progression-free survival, in these patients.

III. Compare pre- vs post-treatment measurements of biomarkers and vascular system/immune system parameters in patients treated with this regimen.

IV. Correlate tumor and blood biomarkers with clinical response in these patients.

OUTLINE: This is a multicenter study.

Patients receive temsirolimus intravenously (IV) over 30 minutes on days 1 and 8 and bevacizumab IV over 30-90 minutes on day 8. Treatment repeats every 14 days for a maximum of 26 courses in the absence of disease progression or unacceptable toxicity. Patients undergo tumor resection on day 9 of course 2.Blood samples are collected during courses 1 and 2. Samples are examined by flow cytometry to evaluate peripheral blood mononuclear cells for molecular effects of study agents. Patients also undergo normal and tumor tissue biopsy (by core needle biopsy, incisional biopsy, or surgical resection) during courses 1 and 2. Samples are examined by immunohistochemistry, western blotting, protein array technology, gene expression analyses, DNA mutation analyses, and genomic analyses for pre-and post-treatment measurements of target molecules (epidermal growth factor receptor, B-Raf, MEK, MAPK), downstream pathway components (PI-3 kinase, AKT, mTOR), markers of angiogenesis, proliferation and apoptosis, markers that may modulate cell signaling or the response to investigational agents, and vascular and immune system parameters.

After completion of study treatment, patients are followed at 1 month, every 3 months for up to 2 years, and then periodically for up to 5 years.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date
Est. primary completion date July 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically or cytologically confirmed melanoma

- Stage III or IV disease

- Recurrent disease allowed

- Measurable disease defined as = 1 lesion that can be accurately measured in = 1 dimension as = 20 mm with conventional techniques OR = 10 mm with spiral CT scan

- Tumor lesions in previously irradiated areas are not considered measurable disease

- Prior brain metastases allowed provided all of the following criteria are met:

- No more than a total of 5 brain metastases

- All metastases are no more than 2.5 cm

- Surgically resected or have been treated with gamma-knife or stereotactic radiosurgery

- More than 30 days since prior disease progression

- More than 30 days since prior steroids for managing brain metastases

- Concurrent steroids for other reasons allowed provided the dose is < that required for managing brain metastases

- Disease accessible for core needle biopsy, incisional biopsy, and/or surgical resection and meets one of the following criteria:

- One large tumor deposit = 5 cm³ from which biopsies can be harvested multiple times

- Multiple deposits that can be biopsied or excised individually on different dates, measured as follows:

- One lesion = 5 cm^3

- Two lesions = 3 cm^3

- Three lesions = 2 cm^3

- ECOG performance status 0-1

- Weight = 110 pounds (without clothes)

- WBC = 3,000 mm³

- Absolute neutrophil count = 1,500/mm³

- Platelet count = 100,000/mm³

- Bilirubin normal

- AST and ALT = 2.5 times upper limit of normal

- Creatinine normal OR creatinine clearance = 60 mL/min

- Urine protein: creatinine ratio < 1.0 OR 24-hour urine protein < 1,000 mg

- Fasting cholesterol < 350 mg/dL (cholesterol medications are allowed)

- Fasting triglycerides < 400 mg/dL

- PT INR = 1.5 (unless on full-dose anticoagulants)

- Hematocrit < 41% (for males) or < 38% (for females)

- None of the following within the past 4 weeks:

- Uncontrolled intercurrent illness

- Ongoing or active acute (CTCAE v.3 grade 3 or 4) infection

- Abdominal fistula

- Gastrointestinal perforation

- Intra-abdominal abscess

- Serious or nonhealing wound, ulcer, or bone fracture

- No psychiatric illness or social situations that would preclude study compliance

- No clinically significant cardiovascular disease, including the following:

- Cerebrovascular accident within the past 6 months

- Transient ischemic attack within the past 6 months

- Myocardial ischemia within the past 6 months

- Myocardial infarction within the past 6 months

- Other thromboembolic event within the past 6 months

- Unstable angina within the past 6 months

- Uncontrolled hypertension (i.e., hypertension despite maximal therapy)

- New York Heart Association class II-IV heart disease

- Congestive heart failure

- Serious cardiac arrhythmia requiring medication

- Clinically significant peripheral vascular disease

- History of stroke

- Artificial valve, pacemaker, or similar device

- No uncontrolled diabetes

- Hemoglobin A1c < 7%

- No significant traumatic injury within the past 28 days

- No history of allergic reactions to compounds of similar chemical or biological composition to temsirolimus or bevacizumab

- No hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies (e.g., infliximab)

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for = 6 months after completion of study treatment

- HIV negative

- Hepatitis C negative

- See Disease Characteristics

- More than 4 weeks since any of the following prior treatments and recovered:

- Chemotherapy (6 weeks for nitrosoureas or mitomycin C)

- Radiotherapy to nontarget lesions or lesions that are not to be biopsied

- Immunotherapy

- Cytokine therapy

- Enzyme-inducing antiepileptic drugs (EIAEDs) or other CYP3A4 inducers

- Investigational agents

- More than 4 weeks since prior major surgery or open biopsy and recovered

- No prior temsirolimus, rapamycin, bevacizumab, or systemic therapies targeted primarily to vascular endothelial growth factor (VEGF), VEGF receptors, or to mTOR inhibition

- Concurrent full-dose anticoagulants (e.g., warfarin/low molecular weight heparin) with PT INR > 1.5 are allowed provided the following criteria are met:

- In-range INR (usually between 2 and 3.5) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin

- No active, clinically significant bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)

- Minimal tumor bleeding of the skin allowed at the clinician's discretion

- No concurrent medications or substances known to affect or with the potential to affect the activity or pharmacokinetics of the following:

- Temsirolimus

- Bevacizumab

- CYP450 isoenzymes

- No concurrent nonstudy-related surgical procedures

- No other concurrent anticancer agents or therapies

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Biological:
Bevacizumab
Given IV
Other:
Laboratory Biomarker Analysis
Correlative studies
Drug:
Temsirolimus
Given IV
Procedure:
Therapeutic Conventional Surgery
Undergo tumor resection

Locations

Country Name City State
United States University of Virginia Cancer Center Charlottesville Virginia
United States Fox Chase Cancer Center Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective tumor response (complete response and partial response) and progression in participants with stage III or IV melanoma following treatment with temsirolimus and bevacizumab Evaluated using Response Evaluation Criteria In Solid Tumor (RECIST) criteria. Day 11 of courses 4, 8, 12, 16, 20, and 24 No
Secondary Adverse events in participants with stage III or IV melanoma treated with temsirolimus and bevacizumab Defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome, or disease which either occurs during the study (having been absent at baseline) or if present at baseline, appears to worsen. Graded using scales found in the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Tabulated by type and severity. Days 1 and 8 of each course Yes
Secondary Association between expression or activation of one biomarker with another, with biochemical and clinical responses, with alterations in cell proliferation and apoptotic markers, and with time to progression Biomarker expression in tumor and normal skin will be assessed by IHC or Western blotting, using marker-specific antibodies. Day 1 of course 1 and day 8 of course 2 No
Secondary Comparison of biomarkers to antitumor activity/patient outcomes Assessed in both tumor tissue and in serum/plasma samples. Day 1 of course 1 and day 8 of course 2 No
Secondary Comparison of pre- vs post-treatment measurements of biomarkers and vascular system/immune system parameters Biomarker expression in tumor and normal skin will be assessed by immunohistochemistry (IHC) or Western blotting, using marker-specific antibodies. Day 1 of course 1 and day 8 of course 2 No
Secondary Progression-free survival Defined as the duration of time from start of treatment to time of progression, death or date of last follow-up. Day 11 of courses 4, 8, 12, 16, 20, and 24, and then annually for up to 5 years No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02224781 - Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Phase 3
Completed NCT02107755 - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT01886235 - Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery N/A
Completed NCT00553306 - Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma Phase 1/Phase 2
Completed NCT00121225 - Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma Phase 2
Completed NCT00019448 - Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT01961115 - Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Phase 2
Completed NCT01748747 - Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery Early Phase 1
Terminated NCT01316692 - Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma Phase 2
Active, not recruiting NCT01120275 - Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma Phase 2
Terminated NCT01166126 - Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV Phase 2
Terminated NCT01217411 - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Phase 1
Completed NCT01037790 - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Phase 2
Completed NCT00288041 - Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT00074308 - Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers Phase 1/Phase 2
Completed NCT00072163 - Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma Phase 2
Completed NCT01989559 - Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery Phase 1
Completed NCT00026143 - Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma Phase 2
Completed NCT00006243 - Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma N/A
Active, not recruiting NCT04284774 - Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Phase 2